• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis.

作者信息

Allinovi Marco, Trivioli Giorgio, Lugli Gianmarco, Villanti Maurizio, Gianassi Iacopo, Antognoli Giulia, Romagnani Paola, Vaglio Augusto, Caroti Leonardo, Cirami Calogero Lino

机构信息

Nephrology, Dialysis and Transplant Unit, Careggi University Hospital, Florence, Italy.

Nephrology Unit, Meyer Children's Hospital and Department of Biomedical Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.

出版信息

Nephrol Dial Transplant. 2022 Mar 25;37(4):789-791. doi: 10.1093/ndt/gfab323.

DOI:10.1093/ndt/gfab323
PMID:34788862
Abstract
摘要

相似文献

1
Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis.蛋白尿选择性指数可预测微小病变病和局灶节段性肾小球硬化症成人患者对利妥昔单抗的反应。
Nephrol Dial Transplant. 2022 Mar 25;37(4):789-791. doi: 10.1093/ndt/gfab323.
2
Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.微小病变病和局灶节段性肾小球硬化症的新兴治疗策略。
Expert Opin Investig Drugs. 2018 Nov;27(11):839-879. doi: 10.1080/13543784.2018.1540587. Epub 2018 Oct 30.
3
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?利妥昔单抗在成人微小病变性肾病和局灶节段性肾小球硬化症中的应用：已知和未知的有哪些？
Autoimmun Rev. 2020 Nov;19(11):102671. doi: 10.1016/j.autrev.2020.102671. Epub 2020 Sep 15.
4
Successful Treatment With Abatacept in Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplant.肾移植后复发性局灶节段性肾小球硬化症使用阿巴西普治疗成功
Exp Clin Transplant. 2019 Jan;17(Suppl 1):178-180. doi: 10.6002/ect.MESOT2018.P53.
5
Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment.利妥昔单抗治疗后复发性局灶节段性肾小球硬化蛋白尿的缓解
N Engl J Med. 2006 May 4;354(18):1961-3. doi: 10.1056/NEJMc055495.
6
A case of recurrent focal segmental glomerulosclerosis after kidney transplantation associated with variant conversion in the Columbia classification.1例肾移植后复发性局灶节段性肾小球硬化症伴哥伦比亚分类中的变异转换
Nephrology (Carlton). 2015 Jul;20 Suppl 2:96-100. doi: 10.1111/nep.12457.
7
Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.利妥昔单抗诱导下成功进行的抢先肾移植治疗局灶节段性肾小球硬化和大量肾病综合征患者：一例报告
Transplant Proc. 2016 Nov;48(9):3092-3094. doi: 10.1016/j.transproceed.2016.07.001.
8
Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.利妥昔单抗治疗微小病变性肾病和局灶节段性肾小球硬化症：4例报告及文献复习
Neth J Med. 2008 Nov;66(10):408-15.
9
Renal disease. II. The treatment of minimal change nephropathy and focal segmental glomerulosclerosis.肾脏疾病。II. 微小病变性肾病和局灶节段性肾小球硬化症的治疗。
J R Coll Physicians Lond. 1997 Mar-Apr;31(2):137-41.
10
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.利妥昔单抗治疗成人微小病变病和局灶节段性肾小球硬化症
Nephron Clin Pract. 2014;128(3-4):277-82. doi: 10.1159/000368590. Epub 2014 Nov 8.

引用本文的文献

1
Comparison and prognostic analysis of focal segmental glomerulosclerosis patients with or without nephrotic syndrome at onset.发病时伴有或不伴有肾病综合征的局灶节段性肾小球硬化患者的比较及预后分析。
BMC Nephrol. 2025 Jul 5;26(1):353. doi: 10.1186/s12882-025-04292-z.
2
Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome.利妥昔单抗治疗依赖类固醇且频繁复发的成人肾病综合征的长期疗效
BMC Nephrol. 2025 Mar 6;26(1):126. doi: 10.1186/s12882-025-04035-0.
3
Kinetic-pharmacodynamic model to predict post-rituximab B-cell repletion as a predictor of relapse in pediatric idiopathic nephrotic syndrome.
预测利妥昔单抗治疗后B细胞恢复情况的药代动力学-药效学模型作为儿童特发性肾病综合征复发的预测指标
Front Pharmacol. 2025 Jan 7;15:1526936. doi: 10.3389/fphar.2024.1526936. eCollection 2024.
4
The proteinuria selectivity index value predicts the remission of IgA nephropathy: a retrospective cohort study.蛋白尿选择性指数值可预测 IgA 肾病的缓解：一项回顾性队列研究。
Ren Fail. 2024 Dec;46(2):2423839. doi: 10.1080/0886022X.2024.2423839. Epub 2024 Nov 4.
5
Clinical relevance of proteinuria selectivity index and fractional excretion of sodium in patients with nephrotic syndrome.蛋白尿选择性指数和钠分数排泄率在肾病综合征患者中的临床意义。
Sci Rep. 2024 Oct 10;14(1):23755. doi: 10.1038/s41598-024-75281-9.
6
Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.成人足细胞病的治疗：欧洲肾脏学会免疫肾脏病学工作组的最新进展。
Nephrol Dial Transplant. 2024 Mar 27;39(4):569-580. doi: 10.1093/ndt/gfae025.
7
Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.低剂量利妥昔单抗治疗微小病变性肾病及预防复发的疗效。
BMC Nephrol. 2023 Apr 26;24(1):112. doi: 10.1186/s12882-023-03092-7.
8
The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult.利妥昔单抗在成人原发性局灶节段性肾小球硬化中的作用
Kidney Int Rep. 2022 May 30;7(8):1878-1886. doi: 10.1016/j.ekir.2022.05.024. eCollection 2022 Aug.
9
Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?利妥昔单抗治疗成人肾病综合征：标准方案还是B细胞靶向治疗？
J Clin Med. 2021 Dec 13;10(24):5847. doi: 10.3390/jcm10245847.